AVEO Oncology, an LG Chem company ("AVEO"), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, presented two posters during the 2025 ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior ...

Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.

Israel's military said a fighter jet targeted a Palestinian militant cell based on intelligence ... 18 Palestinians — only deepen resentment for Israel and prolong the cycle of bloodshed. In a ...

The report of the Joint Committee on Waqf (Amendment) Bill was tabled in the Lok Sabha on Thursday with Home Minister Amit Shah asserting the BJP has no objection to the Opposition’s dissent notes ...

Whether you're shopping for a holistic health connoisseur or a fitness enthusiast, our editors' favorite picks have you ...

Christopher Demos-Brown’s “The Cancellation of Lauren Fein," now on stage at Florida Studio Theatre, is a well-written, ...

Researchers developed a method to recycle all parts of a solar cell repeatedly without environmentally hazardous solvents. The recycled solar cell has the same efficiency as the original one. The ...

Cyclin-dependent kinases (CDKs) are protein kinases involved in critical cellular processes, such as cell cycle or transcription, whose activity requires association with specific cyclin subunits.

Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd ("Kelun-Biotech" will present efficacy and safety results from the ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.